Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.52 |
| ▸ | ITGAL | P20701 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503004 | 0.89 | LTA4H (0.60) | ACEOPRM1OPRD1 | |
| SCHEMBL24933037 | 0.89 | CTSL (0.57) | ACEOPRM1OPRD1CTSLTACR1 | |
| SCHEMBL6655016 | 0.89 | CTSL (0.57) | ACEOPRM1OPRD1CTSLTACR1 | |
| SCHEMBL31593293 | 0.89 | ACE (0.53) | ACEOPRM1OPRD1TACR1 | |
| SCHEMBL15757296 | 0.87 | ERAP2 (0.62) | ACEERAP2P2RY14ALOX15ITGB2 | |
| SCHEMBL29352080 | 0.87 | ERAP2 (0.62) | ACEERAP2P2RY14ALOX15ITGB2 | |
| SCHEMBL15757291 | 0.87 | ERAP2 (0.62) | ACEERAP2P2RY14ALOX15ITGB2 | |
| SCHEMBL30574268 | 0.87 | OPRD1 (0.57) | ACEOPRM1OPRD1 | |
| SCHEMBL9753236 | 0.87 | PRMT1 (0.56) | ACEOPRM1OPRD1ERAP2 | |
| SCHEMBL9753233 | 0.87 | PRMT1 (0.56) | ACEOPRM1OPRD1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009008-A1 | SYNTHETIC GENOME EDITING SYSTEM | PENCIL BIOSCIENCES LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| EP-4636084-A2 | SYNTHETIC GENOME EDITING SYSTEM | Pencil Biosciences Limited (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-4413140-B1 | SYNTHETIC GENOME EDITING SYSTEM | PENCIL BIOSCIENCES LTD (GB) | 2025-08-13 | — | — | EP | disclosed |
| EP-4413140-A1 | SYNTHETIC GENOME EDITING SYSTEM | Pencil Biosciences Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023057777-A1 | SYNTHETIC GENOME EDITING SYSTEM | Pencil Biosciences Limited (GB) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009008-A1 | SYNTHETIC GENOME EDITING SYSTEM | ZFR, CNBP, RPRD2 | ACE 4207/4885OPRM1 3829/4885OPRD1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.